Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor-T Cell Combination Therapy

Version 1 : Received: 15 September 2021 / Approved: 17 September 2021 / Online: 17 September 2021 (09:32:33 CEST)

A peer-reviewed article of this Preprint also exists.

Adhikarla, V.; Awuah, D.; Brummer, A.B.; Caserta, E.; Krishnan, A.; Pichiorri, F.; Minnix, M.; Shively, J.E.; Wong, J.Y.; Wang, X.; Rockne, R.C. A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. Cancers 2021, 13, 5171. Adhikarla, V.; Awuah, D.; Brummer, A.B.; Caserta, E.; Krishnan, A.; Pichiorri, F.; Minnix, M.; Shively, J.E.; Wong, J.Y.; Wang, X.; Rockne, R.C. A Mathematical Modeling Approach for Targeted Radionuclide and Chimeric Antigen Receptor T Cell Combination Therapy. Cancers 2021, 13, 5171.

Journal reference: Cancers 2021, 13, 5171
DOI: 10.3390/cancers13205171

Abstract

Targeted radionuclide therapy (TRT) has recently seen a surge in popularity, with the use of radionuclides conjugated to small molecules and antibodies. Similarly, immunotherapy also has shown promising results – an example being chimeric antigen receptor (CAR) T-cells therapy in hematologic malignancies. Moreover, TRT and CAR T therapies possess unique features that require special consideration when determining how to dose, time, and sequence combination treatments, including the distribution of TRT dose in the body, the decay rate of the radionuclide, and the proliferation and persistence of the CAR-T cells. These characteristics complicate additive or synergistic effects of combination therapies and warrant a mathematical treatment which includes these dynamics in relation to the proliferation and clearance rates of the target tumor cells. Here we combine two previously published mathematical models in a multiple myeloma setting to explore the effects of dose, timing, and sequencing of TRT and CAR-T cell based therapies. We find that for a fixed TRT and CAR-T cell dose, the tumor proliferation rate is the most important parameter in determining the best timing of TRT and CAR T therapies.

Keywords

CAR T; Targeted Radionuclide Therapy; TRT; Mathematical Model; Multiple Myeloma; Immunotherapy; Daratumumab; CS1; Combination Therapy

Subject

MATHEMATICS & COMPUTER SCIENCE, Applied Mathematics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.